This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.

Inclusion Criteria:

• Type 2 diabetes mellitus
• Diet-treated subjects and/or subjects with type 2 diabetes in OAD (oral anti-diabetic drug) mono-therapy
• HbA1c for diet-treated subjects: HbA1c between 6.5-10.0% (both inclusive) and for OAD treated subjects: HbA1c between 6.5-9.5% (both inclusive)
• Body mass index (BMI) between 27-40 kg/m^2 (both inclusive)
• Subjects should have a stable body weight for at least 3 months prior to screening (as documented by a weight within 3 to 6 months, prior to screening that is within 15% of the screening weight)
• Euthyroid subjects
• Subjects should be unrestrained eaters

Exclusion Criteria:

• Recurrent severe hypoglycaemia
• Impaired liver function
• Impaired renal function
• Cardiac problems
• Uncontrolled treated/untreated hypertension
• Known or suspected allergy to trial products or related products
• Use of any drug (except for OADs), which in the investigator's opinion could interfere with the subject's glucose level or body weight
• Active hepatitis B and/or active hepatitis C
• Positive HIV (human immunodeficiency virus) antibodies
• Known or suspected abuse of alcohol or narcotics
• Habitual excessive consumption of methylxanthine-containing beverages and foods (coffee, tea, cola drinks, chocolate) as judged by the Investigator